CANY
ANIP icon

Caxton Associates (New York)’s ANI Pharmaceuticals ANIP Stock Holding History

Caxton Associates (New York)’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,990
Closed -$232K – 461
2023
Q3 		$232K Buy
+3,990
New +$230K 0.03% 341
2022
Q1 		– Sell
-5,471
Closed -$252K – 508
2021
Q4 		$252K Buy
+5,471
New +$235K 0.03% 457

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caxton Associates (New York)'s ANIP Position: Q4 2023 in Review

Caxton Associates (New York) sold out of ANI Pharmaceuticals (ANIP) in Q4 2023, closing a stake of 3,990 shares — an estimated $232K sold.

Caxton Associates (New York) first reported a position in ANIP in Q4 2021 and held it in 2 quarters. The position peaked at $252K in Q4 2021. 181 funds tracked by Wall St. Rank hold ANIP as of Q4 2023.

  • Caxton Associates (New York) reported no remaining ANI Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 3,990 ANI Pharmaceuticals shares in Q4 2023, an estimated $232K.
  • Caxton Associates (New York) first reported a position in ANI Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Caxton Associates (New York)'s ANI Pharmaceuticals position peaked at $252K in Q4 2021.
  • 181 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2023.

Based on Caxton Associates (New York)'s 13F filing for Q4 2023, filed 14 Feb 2024.